

5. China Patent Application No.: 201880032676.5, filed *Date*: May 15, 2018 (E-017-2017-0-CN-05);

6. European Patent Application No.: 18733012.1, filed May 15, 2018 (E-017-2017-0-EP-06);

7. Japan Patent Application No.: 2019-563082, filed November 13, 2019 (E-017-2017-0-JP-07);

8. Korea Patent Application No.: 2019-7017289, filed December 13, 2019, (E-017-2017-0-KR-08);

9. Singapore Patent Application No.: 11201910499V, filed November 11, 2019 (E-017-2017-0-SG-09);

10. United States Patent Application No.: 16/613,187, filed November 13, 2019 (E-017-2017-0-US-10);

The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.

The prospective exclusive license territory may be worldwide, and the fields of use may be limited to the following:

“Development, manufacture and commercialization of chimeric antigen receptor T cell (CAR-T) immunotherapies for the treatment of B cell malignancies, wherein the T cells are:

1. Manufactured *ex vivo*;
2. Not engineered to overexpress CD47;
3. Engineered to express a CAR that targets CD22 via the m971 scFv in combination with both:
 - a. Binders, CARs, or other receptors targeting: CD19, CD20, CD79b, or any combination thereof; and
 - b. At least one of the following:
 - A technology to activate CD2 signaling in the CAR T cell, and/or
 - Manufacturing of the cell product using the Storage by Actuated Shuttling (StASh)

Where “*ex vivo*” specifically means where the cells or tissue are removed from a healthy donor (in the case of allogeneic therapy) or the patient (in the case of autologous therapy), modified *ex vivo* and then, implanted, transplanted, infused, or transferred into the patient.

For purposes of clarity, specifically excluded from these Fields of Use are the following:

1. Allogeneically-derived CAR-T immunotherapies that have been engineered to overexpress CD47;
2. CAR-T immunotherapies wherein the CAR-T cells are manufactured within the patient via gene therapy vectors delivered to the patient (*in vivo* CAR-T immunotherapies);
3. Autologously-derived CAR-T immunotherapies that have been engineered to be specific for CD19, CD20, and CD22 (via the m971 scFv)

absent the engineering of the CAR-T therapies to activate CD2 signaling and/or StASh as described in the Fields of Use 3(b) above;

4. CAR-T immunotherapies wherein the CAR-T cells are engineered to express a bispecific CAR that is engineered to bind to CD19 and CD22, as described in HHS Ref. E-106-2015 and encompassing the m971 scFv and the CD22 CAR.”

The government-owned technologies that are contemplated in this proposed license are CAR therapies that target CD22 by utilizing the anti-CD22 binder known as m971 alone. The E-080-2008 technology encompasses the m971 binder, while E-291-2012 describes a CAR encompassing the m971 binder. Additionally, E-017-2017 describes a bicistronic CAR vector that encompasses the CD22-targeting m971 CAR and a CAR that targets CD19. CD22 is expressed on the surface of B cells in B cell malignancies and CD22-targeting CAR-T has shown early promise in clinical trials for ALL and NHL both as a monospecific and multispecific therapy. Targeting CD22 in combination with other B cell antigens (CD19, CD20, and/or CD79b in this instance) can lead to more effective CAR-T cell therapies.

This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published Notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information from these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: February 23, 2022.

Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2022-04245 Filed 2-28-22; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel; Research Projects in Cancer Systems Biology (CSBC Research Projects) (U01).

Date: March 31, 2022.

Time: 10:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W234, Rockville, Maryland 20850 (Telephone Conference Call).

Contact Person: Adriana Stoica, Ph.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, 7W234, Rockville, Maryland 20850, 240-276-6368, Stoicaa2@mail.nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel; SEP-1 NCI Clinical and Translational R21 and Omnibus R03 Review.

Date: March 31, 2022.

Time: 11:00 a.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W602, Rockville, Maryland 20850 (Telephone Conference Call).

Contact Person: Delia Tang, M.D., Scientific Review Officer, Resources Training and Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W602, Rockville, Maryland 20850, 240-276-6456, tangd@mail.nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel; Social and Behavioral Intervention Research to Address Modifiable Risk Factors for Cancer in Rural Populations (R01).

Date: May 5, 2022.

Time: 10:00 a.m. to 4:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room

7W618, Rockville, Maryland 20850
(Telephone Conference Call).

Contact Person: Mukesh Kumar, Ph.D.,
Scientific Review Officer, Research Program
Review Branch, Division of Extramural
Activities, 9609 Medical Center Drive, Room
7W618, National Cancer Institute, NIH,
Rockville, Maryland 20850, 240-276-6611,
mukesh.kumar3@nih.gov.

(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)

Dated: February 24, 2022.

Melanie J. Pantoja,

*Program Analyst, Office of Federal Advisory
Committee Policy.*

[FR Doc. 2022-04273 Filed 2-28-22; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.

The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.

Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
NHLBI Conference Grant Review R13.

Date: April 7, 2022.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant
applications.

Place: National Institutes of Health, 6705
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).

Contact Person: Tony L. Creazzo, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 207-Q,
Bethesda, MD 20892-7924, (301) 827-7913,
creazzotl@mail.nih.gov.

Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
NHLBI Member Conflict Mentored Career
Development Awards.

Date: April 8, 2022.

Time: 2:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant
applications.

Place: National Institutes of Health, 6705
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).

Contact Person: Lindsay M. Garvin, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Suite 208-Y,
Bethesda, MD 20892, (301) 827-7911,
lindsay.garvin@nih.gov.

Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Multi-site Clinical Trial Special Emphasis
Panel.

Date: April 19, 2022.

Time: 1:00 p.m. to 2:30 p.m.

Agenda: To review and evaluate grant
applications.

Place: National Institutes of Health, 6705
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).

Contact Person: Keary A. Cope, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 209-A,
Bethesda, MD 20892-7924, (301) 827-7912,
copeka@mail.nih.gov.

Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
HEAL Initiative: Opioid Induced Respiratory
Depression.

Date: April 27, 2022.

Time: 11:00 a.m. to 12:00 p.m.

Agenda: To review and evaluate grant
applications.

Place: National Institutes of Health, 6705
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).

Contact Person: Kristin Goltry, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 209-B,
Bethesda, MD 20892, (301) 435-0297,
goltrykl@mail.nih.gov.

Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Pulmonary Trials Cooperative (PTC).

Date: April 28, 2022.

Time: 1:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant
applications.

Place: National Institutes of Health, 6705
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).

Contact Person: Kristen Page, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 209-B,
Bethesda, MD 20892, (301) 827-7953,
kristen.page@nih.gov.

(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)

Dated: February 24, 2022.

David W. Freeman,

*Program Analyst, Office of Federal Advisory
Committee Policy.*

[FR Doc. 2022-04288 Filed 2-28-22; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.

The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.

Name of Committee: Center for Scientific
Review Special Emphasis Panel; Molecular
Neurogenetic Labeling and Imaging
Techniques.

Date: March 23, 2022.

Time: 1:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant
applications.

Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Mary G. Schueler, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5214,
MSC 7846, Bethesda, MD 20892, 301-915-
6301, marygs@csr.nih.gov.

Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Speech, Language and
Communication.

Date: March 25, 2022.

Time: 1:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant
applications.

Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Sara Louise Hargrave,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3170,
Bethesda, MD 20892, (301) 443-7193,
hargravesl@mail.nih.gov.

Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Infectious Diseases and
Immunology.

Date: April 4-5, 2022.

Time: 9:00 a.m. to 6:00 p.m.